18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
| Condition(s) | Esophageal Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment. |
| Who can participate | Inclusion Criteria: 1. Participants must be ≥18 years of age 2. Participants with locally advanced esophageal cancer 3. Participants with untreated documented carcinoma of the esophagus that is \> 2 cm in patients who are going to receive systemic therapy concurrently with radiation as primary therapy are eligible 4. Ability to provide written informed consent in accordance with institutional policies 5. Female participants of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical 6. The effects of 18F-FAraG PET on the developing human fetus are unknown. For this reason and because 18F-FAraG PET agents as well as other therapeutic agents used in this |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | M.D. Anderson Cancer Center |
| Locations | Houston, Texas, United States |
| Start date | 2024-09-04 |
| NCT ID | NCT06414902 |
| Official listing | https://clinicaltrials.gov/study/NCT06414902 |